Table 1.

 Drug‐resistant mutations in patients who received various nucleos(t)ide analogue therapies

Drug usage* (mutant/total)	LAM‐R	ADV‐R	ETV‐R	Coexist‐R	Drug usage (mutant/total)	LAM‐R	ADV‐R	ETV‐R	Coexist‐R
LAM (214/490)	208	–	5	1	LAM→LAM + ADV + ETV (0/1)	–	–	–	–
ADV (35/428)	–	35	–	–	LAM→LAM + ETV (0/1)	–	–	–	–
ETV (0/73)	–	–	–	–	LAM→LAM + ETV→ETV (1/1)	–	–	1	–
LdT (5/18)	5	–	–	–	LAM→LdT (6/10)	6	–	–	–
LAM→ADV (136/381)	87	36	4	9	LAM + ADV (1/15)	1	–	–	–
LAM→ETV (35/77)	25	–	10	–	LAM + ADV→ADV (0/4)	–	–	–	–
LAM→ADV→ETV (38/57)	29	–	8	1	LAM + ADV→ADV→ADV + LdT (1/1)	1	–	–	–
LAM→ETV→ADV (4/7)	4	–	–	–	LAM + ADV→ADV→ETV (1/1)	1	–	–	–
LAM→ADV→ADV + ETV (3/5)	3	–	–	–	LAM + ADV→ETV (0/1)	–	–	–	–
LAM→ADV→ADV + LdT (2/4)	–	–	2	–	LAM→ADV→ETV→ADV→ADV + LAM (1/1)	–	–	–	1
LAM→ADV→ETV→ADV + ETV (1/1)	1	–	–	–	ADV→ETV (1/27)	–	1	–	–
LAM→ADV→LAM→ADV + ETV (1/1)	1	–	–	–	ADV→LAM (3/12)	3	–	–	–
LAM→ADV→LAM + ADV (5/10)	3	–	–	2	ADV→ADV + LAM (2/19)	1	–	–	1
LAM→ADV→LdT (8/12)	7	1	–	–	ADV + LdT (1/3)	–	1	–	–
LAM→ADV + ETV (2/3)	2	–	–	–	ADV→LAM→LAM + ADV (2/3)	1	–	1	–
LAM→ADV + ETV→ADV (1/1)	1	–	–	–	ADV→ETV→LdT (0/1)	–	–	–	–
LAM→ADV + LdT (1/1)	1	–	–	–	ADV→ADV + LdT (0/4)	–	–	–	–
LAM→ETV→ETV + ADV (1/3)	1	–	–	–	ADV→LAM→ETV (1/1)	1	–	–	–
LAM→LAM + ADV (32/82)	30	1	1	–	ADV→LdT (8/23)	3	3	–	2
LAM→LAM + ADV→ADV (3/7)	3	–	–	–	ADV→ADV + ETV (0/1)	–	–	–	–
LAM→LAM + ADV→ADV→ETV (1/1)	–	–	1	–	ETV→ADV (0/3)	–	–	–	–
LAM→LAM + ADV→ETV (1/3)	1	–	–	–	ETV→ETV + ADV (0/3)	–	–	–	–
LAM→LAM + ADV→ETV→LdT (1/1)	1	–	–	–
LAM→LAM + ADV→ETV +  ADV (1/1)	–	–	1	–	Total (560/1803)	431	78	34	17

LAM‐R, ADV‐R and ETV‐R represent lamivudine‐, adefovir‐ and entecavir‐resistant mutations, respectively. Coexist‐R represents coexistence of detectable LAM‐R/ ETV‐R (nucleoside) and ADV‐R (nucleotide) in viral populations.

LdT, telbivudine.

*Each mono‐ or sequential/combined therapy lasted for ≥3 months.